Pan-cancer T cell atlas reveals new details of tumor...
A new study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, provides a...
MD Anderson Research Highlights: ASCO 2023 Special Edition
ABSTRACTS: 398868, 425082, 6546, 3501, 6008, 9502, 9011, 9008
CHICAGO ― The University of Texas MD Anderson Cancer Center’s Research...
ASCO: Luspatercept enables majority of patients with MDS to...
ABSTRACT: 7003
Treatment with luspatercept improved red blood cell counts and erythroid responses compared to treatment with epoetin...
MD Anderson Research Highlights for May 24, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research...
MD Anderson awarded over $5.7 million from Break Through...
The University of Texas MD Anderson Cancer Center was awarded more than $5.7 million in grants from Break Through Cancer to support...
Combined delivery of engineered virus with immunotherapy is...
Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent...
MD Anderson Research Highlights for May 10, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research...
Allison Institute announces appointment of inaugural members
The James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center today announced the appointment of its first...
MD Anderson researchers Helen Piwnica-Worms and Richard...
Two researchers from The University of Texas MD Anderson Cancer Center have been elected to the prestigious National Academy of...